Béranger A, Bouazza N, de Haut de Sigy A, Foubert-Wenc AC, Davous D, Aerts I, Geoerger B, Auvrignon A, Brethon B, Leblond P, Corradini N, André N, Martinez H, Dupont JK, Doz F, Chappuy H. Arch Dis Child. 2018 Nov 24 [Epub ahead of print]
OBJECTIVE: To analyse parents’ and children’s understanding of consent information and assess their decision-making process in paediatric oncology.
DESIGN: Prospective observational study.
SETTINGS: Eleven French paediatric oncology units.
PATIENTS: Parents and children who have been asked to give consent for participation in an early phase trial.
INTERVENTIONS: Thirty-seven children and 119 parents were questioned using an audio-recorded semistructured interview.
MAIN OUTCOME MEASURES: The participants’ understanding of nine elements of the informed consent was assessed by comparing their answers with the informed consent leaflet. Their decision-making process was also evaluated.
RESULTS: Most parents and children had an excellent understanding regarding their participation in a clinical trial (respectively 88.2% and 48.6%), the right to withdraw (76.5% and 43.2%) and the prospects of collective benefits (74.8% and 48.6%). By contrast, less than half of the parents and few of the children correctly understood the alternatives (respectively 47.5% and 27%), the risks related to participation (44.5% and 10.8%), the prospects of individual benefits (33.6% and 10.8%) and the purpose of the clinical trial (12.6% and 2.7%). Twenty-six (70.3%) children participated in the decision-making process. Most parents and children felt they had no choice but to participate in the trial to have access to a new anticancer treatment.
CONCLUSIONS: What might appear to be a poor understanding of the research protocol may actually correspond to the families’ interpretation of the situation as a coping mechanism. All children (except infants) should get age-tailored information in order for them to have a meaningful involvement in research.